Heron Therapeutics maintained its full-year outlook as growth in its Acute Care franchise helped offset ongoing weakness in oncology products during the first quarter.
Key Investor Takeaways
- Heron Therapeutics, Inc. (NASDAQ:HRTX) reaffirmed 2026 revenue guidance of $173 million to $183 million and adjusted EBITDA guidance of $10 million to $20 million.
- Acute Care franchise revenue grew 32% year-over-year, led by ZYNRELEF and APONVIE growth.
- Total Q1 net revenue declined 10.8% to $34.7 million due to weaker oncology sales.
- APONVIE and ZYNRELEF demand trends, reimbursement expansion, and planned sales force growth remain key commercial catalysts.
- Investors may focus on whether Acute Care growth can sustainably offset declining CINVANTI and SUSTOL revenue.
Why Heron Therapeutics Stock Is in Focus
Heron Therapeutics reported first-quarter 2026 net revenue of $34.7 million, down from $38.9 million in the prior-year period.
The decline was driven primarily by lower Oncology Supportive Care revenue, which fell 26.3% year-over-year to $21.1 million.
CINVANTI revenue declined 20.2% to $20.5 million, while SUSTOL revenue dropped sharply as the company continues winding down the product ahead of its planned exit by the end of 2026.
Despite the overall revenue decline, Heron’s Acute Care franchise posted strong growth.
Acute Care revenue rose 32.3% year-over-year to $13.6 million, including ZYNRELEF revenue of $10.2 million and APONVIE revenue of $3.4 million.
The company said ZYNRELEF demand units increased 22% year-over-year, while APONVIE demand units climbed 68%.
Heron also highlighted continued commercial expansion efforts, including planned sales force growth in the third quarter of 2026 and expanded reimbursement access tied to permanent product-specific J-codes for both ZYNRELEF and APONVIE.
CEO Craig Collard stated: “Our Acute Care franchise continues to perform with strong year-over-year growth, and we remain confident in our full-year framework.”
The company ended the quarter with $44.8 million in cash, cash equivalents, and short-term investments.
Why This Matters for Investors
The results reinforce the importance of Heron’s transition toward its Acute Care franchise as legacy oncology products face pressure.
For investors, the central question is whether newer products such as ZYNRELEF and APONVIE can generate enough sustained growth to offset ongoing declines in the Oncology Supportive Care business.
The company’s decision to reaffirm full-year guidance may signal management confidence that improving procedural volumes, reimbursement expansion, and commercial execution can support stronger performance later in the year.
The rollout of permanent J-codes may also improve reimbursement clarity and product adoption, particularly for hospital and surgical center customers.
At the same time, Heron still faces execution risks tied to commercial adoption, sales force expansion, and broader healthcare utilization trends.
Gross margin pressure related to higher-cost CINVANTI inventory also remains a near-term factor investors may monitor over the next several quarters.
Still, the strong demand growth in APONVIE and ZYNRELEF suggests the company is making progress in shifting its revenue mix toward higher-growth Acute Care products.
What To Watch Next
Investors will likely monitor several upcoming developments:
- Growth trends for ZYNRELEF and APONVIE demand units
- Impact of new reimbursement codes on adoption
- Execution of Heron’s planned sales force expansion
- Stabilization or continued erosion in oncology product revenue
- Progress toward the company’s adjusted EBITDA targets
- Development updates tied to the ZYNRELEF prefilled syringe program